KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Gross Margin: 2020-2025

Historic Gross Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -183.81%.

  • Recursion Pharmaceuticals' Gross Margin fell 23750.00% to -183.81% in Q3 2025 from the same period last year, while for Sep 2025 it was -59.01%, marking a year-over-year decrease of 9408.00%. This contributed to the annual value of 23.12% for FY2024, which is 1866.00% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Gross Margin is -183.81%, which was down 3,666.86% from -4.88% recorded in Q2 2025.
  • Recursion Pharmaceuticals' Gross Margin's 5-year high stood at 100.00% during Q1 2021, with a 5-year trough of -183.81% in Q3 2025.
  • In the last 3 years, Recursion Pharmaceuticals' Gross Margin had a median value of -2.59% in 2023 and averaged -26.45%.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Gross Margin surged by 10,023bps in 2023 and then slumped by 23,750bps in 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Gross Margin (Quarterly) stood at 100.00% in 2021, then plummeted by 7,926bps to 20.74% in 2022, then plummeted by 1,146bps to 9.27% in 2023, then slumped by 19,071bps to -181.43% in 2024, then plummeted by 23,750bps to -183.81% in 2025.
  • Its last three reported values are -183.81% in Q3 2025, -4.88% for Q2 2025, and -48.04% during Q1 2025.